Genital graft-versus-host-disease can be a lifelong risk for female stem cell or bone marrow transplant recipients. The presentation reviews the symptoms of vaginal and vulvar GVHD and discusses treatments that can restore women to full sexual health and functioning. Many thanks to Kadmon, a Sanofi company, and Syndax Pharmaceuticals, whose support, in part, made this webinar possible.